Apolikhin O I, Aliaev Iu G, Sivkov A V, Vinarov A Z, Oshchepkov V N, Keshishev N G, Bedretdinova D A, Akhvlediani N D
Urologiia. 2010 Jan-Feb(1):29-34.
The trial of efficacy and safety of two doses of the drug cernilton in patients with chronic abacterial prostatitis made in the Research Institute of Urology and I.M. Sechenov Medical Academy in 2008 gave evidence for subjective (NIH-CPSI, Sex-4, IPSS and other scales, QOL) and objective (leucocyte count in prostatic secretion) pronounced anti-inflammatory effects of the drug which persist for at least 6 months. Comparison of the two doses of cernilton showed significant differences in subjective response of the patients (NIH-CPSI and Symptom Frequency Scale). Cernilton is recommended as a medication of choice for treatment of patients with chronic abacterial prostatitis.
2008年，泌尿外科研究所和谢马什克夫医学科学院对两剂药“舍尼通”治疗慢性非细菌性前列腺炎患者的疗效和安全性进行了试验，结果表明该药具有显著的主观（美国国立卫生研究院慢性前列腺炎症状指数、性健康量表、国际前列腺症状评分等量表、生活质量）和客观（前列腺分泌物白细胞计数）抗炎作用，且至少持续6个月。对两剂舍尼通的比较显示，患者的主观反应（美国国立卫生研究院慢性前列腺炎症状指数和症状频率量表）存在显著差异。舍尼通被推荐为治疗慢性非细菌性前列腺炎患者的首选药物。
